Current status of molecular markers for early detection of sporadic pancreatic cancer

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1815, Issue 1, 2011, Pages 44-64

  Chakraborty, Subhankar ^a   Baine, Michael J ^b   Sasson, Aaron R ^a,b   Batra, Surinder K ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Biomarkers; Diagnosis; PanIN

Indexed keywords

ALPHA 2 MACROGLOBULIN; AMILORIDE SENSITIVE ACTION CHANNEL 2; APOLIPOPROTEIN A4; BIOLOGICAL MARKER; CALDESMON; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4A; CYTOKERATIN 20; FETUIN A; FIBRONECTIN 1; HEMATOPOIETIC CELL KINASE; INTERSTITIAL COLLAGENASE; LIPOCORTIN 1; LIPOCORTIN 2; MATRILYSIN; MATRIX METALLOPROTEINASE 17; MENKES PROTEIN; MICRORNA; MOLECULAR MARKER; MUCIN 1; PLASTIN 3; PROTEIN; PROTEIN KINASE LKB1; S100 CALCIUM BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 2; THROMBOSPONDIN 2; TRANSMEMBRANE MUCIN; TREFOIL FACTOR 1; TREFOIL FACTOR 2; UNCLASSIFIED DRUG;

ADVANCED CANCER; AMINO ACID SEQUENCE; CANCER PATIENT; CANCER RESISTANCE; CANCER RISK; CANCER SCREENING; EARLY DIAGNOSIS; ENDOSCOPIC ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FAMILIAL CANCER; FAMILY HISTORY; HUMAN; LETHALITY; METASTASIS; MORTALITY; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEOTIDE SEQUENCE; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SPORADIC PANCREAS CANCER;

ADENOCARCINOMA; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; ENDOSONOGRAPHY; HUMANS; LIFE STYLE; MICRORNAS; PANCREATIC NEOPLASMS; PANCREATITIS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 78650582001     PISSN: 0304419X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbcan.2010.09.002     Document Type: Review

References (199)

1. Slack J.M. Developmental biology of the pancreas. Development 1995, 121:1569-1580.
2. National Diabetes Statistics, 2007 Fact Sheet, U.S. Department of Health and Human Services, National Institutes of Health, Bethesda, MD 2008, National Institute of Diabetes and Digestive and Kidney Diseases.
3. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J. Clin. 2009, 59:225-249.
4. Pour P.M., Pandey K.K., Batra S.K. What is the origin of pancreatic adenocarcinoma?. Mol. Cancer 2003, 2:13.
5. Murtaugh L.C., Leach S.D. A case of mistaken identity? Nonductal origins of pancreatic "ductal" cancers. Cancer Cell 2007, 11:211-213.
6. Sipos B., Frank S., Gress T., Hahn S., Kloppel G. Pancreatic intraepithelial neoplasia revisited and updated. Pancreatology 2009, 9:45-54.
7. Ottenhof N.A., Milne A.N., Morsink F.H., Drillenburg P., Ten Kate F.J., Maitra A., Offerhaus G.J. Pancreatic intraepithelial neoplasia and pancreatic tumorigenesis: of mice and men. Arch. Pathol. Lab. Med. 2009, 133:375-381.
8. Sohn T.A., Yeo C.J., Cameron J.L., Hruban R.H., Fukushima N., Campbell K.A., Lillemoe K.D. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann. Surg. 2004, 239:788-797.
9. Takaori K. Current understanding of precursors to pancreatic cancer. J. Hepatobiliary-Pancreat. Surg. 2007, 14:217-223.
10. Crawford James M. Biliary tract and pancreas tissue processing techniques. Surgical Pathology of the GI tract, Liver, Biliary Tract and Pancreas 2009, 765-782. Saunders Elsevier. R.D. Odze, J.R. Goldblum (Eds.).
11. Katabi N., Klimstra D.S. Intraductal papillary mucinous neoplasms of the pancreas: clinical and pathological features and diagnostic approach. J. Clin. Pathol. 2008, 61:1303-1313.
12. Sarr M.G., Carpenter H.A., Prabhakar L.P., Orchard T.F., Hughes S., van Heerden J.A., DiMagno E.P. Clinical and pathologic correlation of 84 mucinous cystic neoplasms of the pancreas: can one reliably differentiate benign from malignant (or premalignant) neoplasms?. Ann. Surg. 2000, 231:205-212.
13. Zanini N., Fantini L., Casadei R., Pezzilli R., Santini D., Calculli L., Minni F. Serous cystic tumors of the pancreas: when to observe and when to operate: a single-center experience. Dig. Surg. 2008, 25:233-239.
14. Ghaneh P., Costello E., Neoptolemos J.P. Biology and management of pancreatic cancer. Postgrad. Med. J. 2008, 84:478-497.
15. Sultana A., Ghaneh P., Cunningham D., Starling N., Neoptolemos J.P., Smith C.T. Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison. BMC Cancer 2008, 8:192.
16. Michalski C.W., Weitz J., Buchler M.W. Surgery insight: surgical management of pancreatic cancer. Nat. Clin. Pract. Oncol. 2007, 4:526-535.
17. Karhu R., Mahlamaki E., Kallioniemi A. Pancreatic adenocarcinoma - genetic portrait from chromosomes to microarrays. Genes Chromosom. Cancer 2006, 45:721-730.
18. O'Reilly E.M. Pancreatic adenocarcinoma: new strategies for success. Gastrointest. Cancer Res. 2009, 3:S11-S15.
19. Feldmann G., Maitra A. Molecular genetics of pancreatic ductal adenocarcinomas and recent implications for translational efforts. J. Mol. Diagn. 2008, 10:111-122.
20. Lowenfels A.B., Maisonneuve P., Cavallini G., Ammann R.W., Lankisch P.G., Andersen J.R., Dimagno E.P., Andren-Sandberg A., Domellof L. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N. Engl. J. Med. 1993, 328:1433-1437.
21. Holly E.A., Chaliha I., Bracci P.M., Gautam M. Signs and symptoms of pancreatic cancer: a population-based case-control study in the San Francisco Bay area. Clin. Gastroenterol. Hepatol. 2004, 2:510-517.
22. Porta M., Fabregat X., Malats N., Guarner L., Carrato A., de M.A., Ruiz L., Jariod M., Costafreda S., Coll S., Alguacil J., Corominas J.M., Sola R., Salas A., Real F.X. Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. Clin. Transl. Oncol. 2005, 7:189-197.
23. Berrington de G.A., Sweetland S., Spencer E. A meta-analysis of obesity and the risk of pancreatic cancer. Br. J. Cancer 2003, 89:519-523.
24. Patel A.V., Rodriguez C., Bernstein L., Chao A., Thun M.J., Calle E.E. Obesity, recreational physical activity, and risk of pancreatic cancer in a large U.S. Cohort. Cancer Epidemiol. Biomark. Prev. 2005, 14:459-466.
25. Anderson L.N., Cotterchio M., Gallinger S. Lifestyle, dietary, and medical history factors associated with pancreatic cancer risk in Ontario, Canada. Cancer Causes Control 2009, 20:825-834.
26. Villeneuve P.J., Johnson K.C., Mao Y., Hanley A.J. Environmental tobacco smoke and the risk of pancreatic cancer: findings from a Canadian population-based case-control study. Can. J. Public Health 2004, 95:32-37.
27. Hanley A.J., Johnson K.C., Villeneuve P.J., Mao Y. Physical activity, anthropometric factors and risk of pancreatic cancer: results from the Canadian enhanced cancer surveillance system. Int. J. Cancer 2001, 94:140-147.
28. Villeneuve P.J., Johnson K.C., Hanley A.J., Mao Y. Alcohol, tobacco and coffee consumption and the risk of pancreatic cancer: results from the Canadian Enhanced Surveillance System case-control project. Canadian Cancer Registries Epidemiology Research Group. Eur. J. Cancer Prev. 2000, 9:49-58.
29. Olson S.H., Orlow I., Simon J., Tommasi D., Roy P., Bayuga S., Ludwig E., Zauber A.G., Kurtz R.C. Allergies, variants in IL-4 and IL-4R alpha genes, and risk of pancreatic cancer. Cancer Detect. Prev. 2007, 31:345-351.
30. Bonelli L., Aste H., Bovo P., Cavallini G., Felder M., Gusmaroli R., Morandini E., Ravelli P., Briglia R., Lombardo L., De M.A., Pugliese V. Exocrine pancreatic cancer, cigarette smoking, and diabetes mellitus: a case-control study in northern Italy. Pancreas 2003, 27:143-149.
31. Efthimiou E., Crnogorac-Jurcevic T., Lemoine N.R., Brentnall T.A. Inherited predisposition to pancreatic cancer. Gut 2001, 48:143-147.
32. Rulyak S.J., Lowenfels A.B., Maisonneuve P., Brentnall T.A. Risk factors for the development of pancreatic cancer in familial pancreatic cancer kindreds. Gastroenterology 2003, 124:1292-1299.
33. McWilliams R.R., Bamlet W.R., Cunningham J.M., Goode E.L., de A.M., Boardman L.A., Petersen G.M. Polymorphisms in DNA repair genes, smoking, and pancreatic adenocarcinoma risk. Cancer Res. 2008, 68:4928-4935.
34. Coughlin S.S., Calle E.E., Patel A.V., Thun M.J. Predictors of pancreatic cancer mortality among a large cohort of United States adults. Cancer Causes Control 2000, 11:915-923.
35. Bradley M.C., Hughes C.M., Cantwell M.M., Napolitano G., Murray L.J. Non-steroidal anti-inflammatory drugs and pancreatic cancer risk: a nested case-control study. Br. J. Cancer 2010, 102:1415-1421.
36. Landi S. Genetic predisposition and environmental risk factors to pancreatic cancer: a review of the literature. Mutat. Res. 2009, 681:299-307.
37. Brand R.E., Lerch M.M., Rubinstein W.S., Neoptolemos J.P., Whitcomb D.C., Hruban R.H., Brentnall T.A., Lynch H.T., Canto M.I. Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut 2007, 56:1460-1469.
38. Greer J.B., Lynch H.T., Brand R.E. Hereditary pancreatic cancer: a clinical perspective. Best Pract. Res. Clin. Gastroenterol. 2009, 23:159-170.
39. Brose M.S., Rebbeck T.R., Calzone K.A., Stopfer J.E., Nathanson K.L., Weber B.L. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J. Natl. Cancer Inst. 2002, 94:1365-1372.
40. Rozenblum E., Schutte M., Goggins M., Hahn S.A., Panzer S., Zahurak M., Goodman S.N., Sohn T.A., Hruban R.H., Yeo C.J., Kern S.E. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res. 1997, 57:1731-1734.
41. Borg A., Sandberg T., Nilsson K., Johannsson O., Klinker M., Masback A., Westerdahl J., Olsson H., Ingvar C. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J. Natl. Cancer Inst. 2000, 92:1260-1266.
42. Bartsch D.K., Sina-Frey M., Lang S., Wild A., Gerdes B., Barth P., Kress R., Grutzmann R., Colombo-Benkmann M., Ziegler A., Hahn S.A., Rothmund M., Rieder H. CDKN2A germline mutations in familial pancreatic cancer. Ann. Surg. 2002, 236:730-737.
43. Tersmette A.C., Petersen G.M., Offerhaus G.J., Falatko F.C., Brune K.A., Goggins M., Rozenblum E., Wilentz R.E., Yeo C.J., Cameron J.L., Kern S.E., Hruban R.H. Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin. Cancer Res. 2001, 7:738-744.
44. Xia B., Sheng Q., Nakanishi K., Ohashi A., Wu J., Christ N., Liu X., Jasin M., Couch F.J., Livingston D.M. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol. Cell 2006, 22:719-729.
45. Reid S., Schindler D., Hanenberg H., Barker K., Hanks S., Kalb R., Neveling K., Kelly P., Seal S., Freund M., Wurm M., Batish S.D., Lach F.P., Yetgin S., Neitzel H., Ariffin H., Tischkowitz M., Mathew C.G., Auerbach A.D., Rahman N. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat. Genet. 2007, 39:162-164.
46. Heikkinen T., Karkkainen H., Aaltonen K., Milne R.L., Heikkila P., Aittomaki K., Blomqvist C., Nevanlinna H. The breast cancer susceptibility mutation PALB2 1592delT is associated with an aggressive tumor phenotype. Clin. Cancer Res. 2009, 15:3214-3222.
47. Jones S., Hruban R.H., Kamiyama M., Borges M., Zhang X., Parsons D.W., Lin J.C., Palmisano E., Brune K., Jaffee E.M., Iacobuzio-Donahue C.A., Maitra A., Parmigiani G., Kern S.E., Velculescu V.E., Kinzler K.W., Vogelstein B., Eshleman J.R., Goggins M., Klein A.P. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009, 324:217.
48. Rahman N., Seal S., Thompson D., Kelly P., Renwick A., Elliott A., Reid S., Spanova K., Barfoot R., Chagtai T., Jayatilake H., McGuffog L., Hanks S., Evans D.G., Eccles D., Easton D.F., Stratton M.R. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat. Genet. 2007, 39:165-167.
49. Pogue-Geile K.L., Chen R., Bronner M.P., Crnogorac-Jurcevic T., Moyes K.W., Dowen S., Otey C.A., Crispin D.A., George R.D., Whitcomb D.C., Brentnall T.A. Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism. PLoS. Med. 2006, 3:e516.
50. Klein A.P., Borges M., Griffith M., Brune K., Hong S.M., Omura N., Hruban R.H., Goggins M. Absence of deleterious palladin mutations in patients with familial pancreatic cancer. Cancer Epidemiol. Biomark. Prev. 2009, 18:1328-1330.
51. Slater E., Amrillaeva V., Fendrich V., Bartsch D., Earl J., Vitone L.J., Neoptolemos J.P., Greenhalf W. Palladin mutation causes familial pancreatic cancer: absence in European families. PLoS Med. 2007, 4:e164.
52. Zogopoulos G., Rothenmund H., Eppel A., Ash C., Akbari M.R., Hedley D., Narod S.A., Gallinger S. The P239S palladin variant does not account for a significant fraction of hereditary or early onset pancreas cancer. Hum. Genet. 2007, 121:635-637.
53. Earl J., Yan L., Vitone L.J., Risk J., Kemp S.J., McFaul C., Neoptolemos J.P., Greenhalf W., Kress R., Sina-Frey M., Hahn S.A., Rieder H., Bartsch D.K. Evaluation of the 4q32-34 locus in European familial pancreatic cancer. Cancer Epidemiol. Biomark. Prev. 2006, 15:1948-1955.
54. LaFemina J., Roberts P.A., Hung Y.P., Gusella J.F., Sahani D., Fernandez-del C.C., Warshaw A.L., Thayer S.P. Identification of a novel kindred with familial pancreatitis and pancreatic cancer. Pancreatology 2009, 9:273-279.
55. Wolpin B.M., Chan A.T., Hartge P., Chanock S.J., Kraft P., Hunter D.J., Giovannucci E.L., Fuchs C.S. ABO blood group and the risk of pancreatic cancer. J. Natl. Cancer Inst. 2009, 101:424-431.
56. McWhorter W.P. Allergy and risk of cancer. A prospective study using NHANESI follow up data. Cancer 1988, 62:451-455.
57. Vena J.E., Bona J.R., Byers T.E., Middleton E., Swanson M.K., Graham S. Allergy-related diseases and cancer: an inverse association. Am. J. Epidemiol. 1985, 122:66-74.
58. Turner M.C., Chen Y., Krewski D., Ghadirian P., Thun M.J., Calle E.E. Cancer mortality among US men and women with asthma and hay fever. Am. J. Epidemiol. 2005, 162:212-221.
59. Kadlubar S., Anderson J.P., Sweeney C., Gross M.D., Lang N.P., Kadlubar F.F., Anderson K.E. Phenotypic CYP2A6 variation and the risk of pancreatic cancer. JOP 2009, 10:263-270.
60. Wang L., Bamlet W.R., de A.M., Boardman L.A., Cunningham J.M., Thibodeau S.N., Petersen G.M. Mitochondrial genetic polymorphisms and pancreatic cancer risk. Cancer Epidemiol. Biomark. Prev. 2007, 16:1455-1459.
61. Halfdanarson T.R., Wang L., Bamlet W.R., de A.M., McWilliams R.R., Cunningham J.M., Petersen G.M. Mitochondrial genetic polymorphisms do not predict survival in patients with pancreatic cancer. Cancer Epidemiol. Biomark. Prev. 2008, 17:2512-2513.
62. Diergaarde B., Brand R., Lamb J., Cheong S.Y., Stello K., Barmada M.M., Feingold E., Whitcomb D.C. Pooling-based genome-wide association study implicates gamma-glutamyltransferase 1 (GGT1) gene in pancreatic carcinogenesis. Pancreatology 2010, 10:194-200.
63. Petersen G.M., Amundadottir L., Fuchs C.S., Kraft P., Stolzenberg-Solomon R.Z., Jacobs K.B., Arslan A.A., Bueno-de-Mesquita H.B., Gallinger S., Gross M., Helzlsouer K., Holly E.A., Jacobs E.J., Klein A.P., Lacroix A., Li D., Mandelson M.T., Olson S.H., Risch H.A., Zheng W., Albanes D., Bamlet W.R., Berg C.D., Boutron-Ruault M.C., Buring J.E., Bracci P.M., Canzian F., Clipp S., Cotterchio M., de A.M., Duell E.J., Gaziano J.M., Giovannucci E.L., Goggins M., Hallmans G., Hankinson S.E., Hassan M., Howard B., Hunter D.J., Hutchinson A., Jenab M., Kaaks R., Kooperberg C., Krogh V., Kurtz R.C., Lynch S.M., McWilliams R.R., Mendelsohn J.B., Michaud D.S., Parikh H., Patel A.V., Peeters P.H., Rajkovic A., Riboli E., Rodriguez L., Seminara D., Shu X.O., Thomas G., Tjonneland A., Tobias G.S., Trichopoulos D., Van Den Eeden S.K., Virtamo J., Wactawski-Wende J., Wang Z., Wolpin B.M., Yu H., Yu K., Zeleniuch-Jacquotte A., Fraumeni J.F., Hoover R.N., Hartge P., Chanock S.J. A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat. Genet. 2010, 42:224-228.
64. Jiao L., Hassan M.M., Bondy M.L., Wolff R.A., Evans D.B., Abbruzzese J.L., Li D. XRCC2 and XRCC3 gene polymorphism and risk of pancreatic cancer. Am. J. Gastroenterol. 2008, 103:360-367.
65. Jiao L., Hassan M.M., Bondy M.L., Abbruzzese J.L., Evans D.B., Li D. The XPD Asp312Asn and Lys751Gln polymorphisms, corresponding haplotype, and pancreatic cancer risk. Cancer Lett. 2007, 245:61-68.
66. Tsirambidis J.V., Conwell D.L., Zuccaro G. Chronic pancreatitis. MedGenMed. 2003, 5:17.
67. Etemad B., Whitcomb D.C. Chronic pancreatitis: diagnosis, classification, and new genetic developments. Gastroenterology 2001, 120:682-707.
68. Uomo G., Rabitti P.G. Chronic pancreatitis: relation to acute pancreatitis and pancreatic cancer. Ann. Ital. Chir. 2000, 71:17-21.
69. Pho-Iam T., Thongnoppakhun W., Yenchitsomanus P.T., Limwongse C. A Thai family with hereditary pancreatitis and increased cancer risk due to a mutation in PRSS1 gene. World J. Gastroenterol. 2005, 11:1634-1638.
70. Howes N., Greenhalf W., Stocken D.D., Neoptolemos J.P. Cationic trypsinogen mutations and pancreatitis. Clin. Lab. Med. 2005, 25:39-59.
71. McKay C.J., Glen P., McMillan D.C. Chronic inflammation and pancreatic cancer. Best. Pract. Res. Clin. Gastroenterol. 2008, 22:65-73.
72. Canto M.I., Goggins M., Hruban R.H., Petersen G.M., Giardiello F.M., Yeo C., Fishman E.K., Brune K., Axilbund J., Griffin C., Ali S., Richman J., Jagannath S., Kantsevoy S.V., Kalloo A.N. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin. Gastroenterol. Hepatol. 2006, 4:766-781.
73. Bhanot U.K., Moller P. Mechanisms of parenchymal injury and signaling pathways in ectatic ducts of chronic pancreatitis: implications for pancreatic carcinogenesis. Lab. Invest. 2009, 89:489-497.
74. Raimondi S., Lowenfels A.B., Morselli-Labate A.M., Maisonneuve P., Pezzilli R. Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. Best. Pract. Res. Clin. Gastroenterol. 2010, 24:349-358.
75. Marrache F., Tu S.P., Bhagat G., Pendyala S., Osterreicher C.H., Gordon S., Ramanathan V., Penz-Osterreicher M., Betz K.S., Song Z., Wang T.C. Overexpression of interleukin-1beta in the murine pancreas results in chronic pancreatitis. Gastroenterology 2008, 135:1277-1287.
76. Algul H., Treiber M., Lesina M., Schmid R.M. Mechanisms of disease: chronic inflammation and cancer in the pancreas-a potential role for pancreatic stellate cells?. Nat. Clin. Pract. Gastroenterol. Hepatol. 2007, 4:454-462.
77. Banks P.A. Classification and diagnosis of chronic pancreatitis. J. Gastroenterol. 2007, 42(Suppl 17):148-151.
78. LaFemina J., Roberts P.A., Hung Y.P., Gusella J.F., Sahani D., Fernandez-del C.C., Warshaw A.L., Thayer S.P. Identification of a novel kindred with familial pancreatitis and pancreatic cancer. Pancreatology 2009, 9:273-279.
79. Carriere C., Young A.L., Gunn J.R., Longnecker D.S., Korc M. Acute pancreatitis markedly accelerates pancreatic cancer progression in mice expressing oncogenic Kras. Biochem. Biophys. Res. Commun. 2009, 382:561-565.
80. Paramythiotis D., Kleeff J., Schmidt J., Buchler M., Friess H. Detection of oncogenes in chronic pancreatitis. HPB (Oxford) 2003, 5:214-225.
81. Logsdon C.D., Simeone D.M., Binkley C., Arumugam T., Greenson J.K., Giordano T.J., Misek D.E., Kuick R., Hanash S. Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res. 2003, 63:2649-2657.
82. Deng R., Lu Z., Chen Y., Zhou L., Lu X. Plasma proteomic analysis of pancreatic cancer by 2-dimensional gel electrophoresis. Pancreas 2007, 34:310-317.
83. Chen Y., Zheng B., Robbins D.H., Lewin D.N., Mikhitarian K., Graham A., Rumpp L., Glenn T., Gillanders W.E., Cole D.J., Lu X., Hoffman B.J., Mitas M. Accurate discrimination of pancreatic ductal adenocarcinoma and chronic pancreatitis using multimarker expression data and samples obtained by minimally invasive fine needle aspiration. Int. J. Cancer 2007, 120:1511-1517.
84. Nash J.W., Bhardwaj A., Wen P., Frankel W.L. Maspin is useful in the distinction of pancreatic adenocarcinoma from chronic pancreatitis: a tissue microarray based study. Appl. Immunohistochem. Mol. Morphol. 2007, 15:59-63.
85. Bhardwaj A., Marsh W.L., Nash J.W., Barbacioru C.C., Jones S., Frankel W.L. Double immunohistochemical staining with MUC4/p53 is useful in the distinction of pancreatic adenocarcinoma from chronic pancreatitis: a tissue microarray-based study. Arch. Pathol. Lab. Med. 2007, 131:556-562.
86. Chen R., Brentnall T.A., Pan S., Cooke K., Moyes K.W., Lane Z., Crispin D.A., Goodlett D.R., Aebersold R., Bronner M.P. Quantitative proteomics analysis reveals that proteins differentially expressed in chronic pancreatitis are also frequently involved in pancreatic cancer. Mol. Cell. Proteomics 2007, 6:1331-1342.
87. Crnogorac-Jurcevic T., Gangeswaran R., Bhakta V., Capurso G., Lattimore S., Akada M., Sunamura M., Prime W., Campbell F., Brentnall T.A., Costello E., Neoptolemos J., Lemoine N.R. Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma. Gastroenterology 2005, 129:1454-1463.
88. Egawa N., Tu Y., Sanaka M., Kamisawa T. Family history of diabetes and pancreatic cancer. Pancreas 2005, 30:15-19.
89. Chari S.T., Leibson C.L., Rabe K.G., Ransom J., de A.M., Petersen G.M. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 2005, 129:504-511.
90. Correa-Gallego C., Ferrone C., Sahani D., Forcione D., Brugge W., Thayer S.P., Warshaw A.L., Fernandez-del Castillo C. Incidentally Discovered Pancreatic Cysts: What Evaluation is Useful? 2008, 466.
91. Varadarajulu S., Tamhane A., Eloubeidi M.A. Yield of EUS-guided FNA of pancreatic masses in the presence or the absence of chronic pancreatitis. Gastrointest. Endosc. 2005, 62:728-736.
92. Sahai A.V., Mishra G., Penman I.D., Williams D., Wallace M.B., Hadzijahic N., Pearson A., Vanvelse A., Hoffman B.J., Hawes R.H. EUS to detect evidence of pancreatic disease in patients with persistent or nonspecific dyspepsia. Gastrointest. Endosc. 2000, 52:153-159.
93. Varadarajulu S., Tamhane A., Eloubeidi M.A. Yield of EUS-guided FNA of pancreatic masses in the presence or the absence of chronic pancreatitis. Gastrointest. Endosc. 2005, 62:728-736.
94. LeBlanc J.K., Ciaccia D., Al-Assi M.T., McGrath K., Imperiale T., Tao L.C., Vallery S., DeWitt J., Sherman S., Collins E. Optimal number of EUS-guided fine needle passes needed to obtain a correct diagnosis. Gastrointest. Endosc. 2004, 59:475-481.
95. Saftoiu A., Iordache S., Gheonea D.I., Popescu C., Malos A., Gorunescu F., Ciurea T., Iordache A., Popescu G.L., Manea C. Combined contrast-enhanced power Doppler and real-time sonoelastography performed during EUS, used in the differential diagnosis of focal pancreatic masses (with videos). Gastrointest. Endosc. 2010, 72:739-747.
96. Volmar K.E., Vollmer R.T., Jowell P.S., Nelson R.C., Xie H.B. Pancreatic FNA in 1000 cases: a comparison of imaging modalities. Gastrointest. Endosc. 2005, 61:854-861.
97. Khalid A., Funch-Jensen P., Bendix J., Dutoit H.S., Kruse A., Viborg M.F. Intraductal papillary mucinous tumor of the pancreas (IPMT): follow-up of twelve cases. Scand. J. Surg. 2009, 98:25-29.
98. Terris B., Blaveri E., Crnogorac-Jurcevic T., Jones M., Missiaglia E., Ruszniewski P., Sauvanet A., Lemoine N.R. Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. Am. J. Pathol. 2002, 160:1745-1754.
99. Fieger A.J., Demmel N., Mundel D.F., Schenck R.M., Harnisch T., Nussler N.C. Carcinoma of the pancreas at the site of an intraductal papillary mucinous neoplasia. Zentralbl. Chir. 2009, 134:182-185.
100. Ferrone C.R., Correa-Gallego C., Warshaw A.L., Brugge W.R., Forcione D.G., Thayer S.P., Fernandez-del C.C. Current trends in pancreatic cystic neoplasms. Arch. Surg. 2009, 144:448-454.
101. Sahani D.V., Shah Z.K., Catalano O.A., Boland G.W., Brugge W.R. Radiology of pancreatic adenocarcinoma: current status of imaging. J Gastroenterol. Hepatol. 2008, 23:23-33.
102. Kinney T. Evidence-based imaging of pancreatic malignancies. Surg. Clin. N. Am. 2010, 90:235-249.
103. Fritcher E.G., Kipp B.R., Halling K.C., Oberg T.N., Bryant S.C., Tarrell R.F., Gores G.J., Levy M.J., Clayton A.C., Sebo T.J., Roberts L.R. A multivariable model using advanced cytologic methods for the evaluation of indeterminate pancreatobiliary strictures. Gastroenterology 2009, 136:2180-2186.
104. Yong K.T., Ding H., Roy I., Law W.C., Bergey E.J., Maitra A., Prasad P.N. Imaging pancreatic cancer using bioconjugated InP quantum dots. ACS Nano 2009, 3:502-510.
105. Bausch D., Castillo C., Warshaw L.A., Thayer S.P., Kelly K. Plectin-1 as a Novel Imaging Marker in Pancreatic Cancer 2008, 462.
106. Yong K.T. Mn-doped near-infrared quantum dots as multimodal targeted probes for pancreatic cancer imaging. Nanotechnology 2009, 20:15102.
107. Turzhitsky V., Liu Y., Hasabou N., Goldberg M., Roy H.K., Backman V., Brand R. Investigating population risk factors of pancreatic cancer by evaluation of optical markers in the duodenal mucosa. Dis. Markers 2008, 25:313-321.
108. Buchholz M., Braun M., Heidenblut A., Kestler H.A., Kloppel G., Schmiegel W., Hahn S.A., Luttges J., Gress T.M. Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions. Oncogene 2005, 24:6626-6636.
109. Gold D.V., Karanjawala Z., Modrak D.E., Goldenberg D.M., Hruban R.H. PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma. Clin. Cancer Res. 2007, 13:7380-7387.
110. Moll R., Lowe A., Laufer J., Franke W.W. Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am. J. Pathol. 1992, 140:427-447.
111. Duxbury M.S., Matros E., Clancy T., Bailey G., Doff M., Zinner M.J., Ashley S.W., Maitra A., Redston M., Whang E.E. CEACAM6 is a novel biomarker in pancreatic adenocarcinoma and PanIN lesions. Ann. Surg. 2005, 241:491-496.
112. Lee K.M., Cao D., Itami A., Pour P.M., Hruban R.H., Maitra A., Ouellette M.M. Class III beta-tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia. Histopathology 2007, 51:539-546.
113. Sitek B., Sipos B., Alkatout I., Poschmann G., Stephan C., Schulenborg T., Marcus K., Luttges J., Dittert D.D., Baretton G., Schmiegel W., Hahn S.A., Kloppel G., Meyer H.E., Stuhler K. Analysis of the pancreatic tumor progression by a quantitative proteomic approach and immunohistochemical validation. J. Proteome Res. 2009, 8:1647-1656.
114. Pan S., Chen R., Reimel B.A., Crispin D.A., Mirzaei H., Cooke K., Coleman J.F., Lane Z., Bronner M.P., Goodlett D.R., McIntosh M.W., Traverso W., Aebersold R., Brentnall T.A. Quantitative proteomics investigation of pancreatic intraepithelial neoplasia. Electrophoresis 2009, 30:1132-1144.
115. Lee K.M., Cao D., Itami A., Pour P.M., Hruban R.H., Maitra A., Ouellette M.M. Class III beta-tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia. Histopathology 2007, 51:539-546.
116. Karanjawala Z.E., Illei P.B., Ashfaq R., Infante J.R., Murphy K., Pandey A., Schulick R., Winter J., Sharma R., Maitra A., Goggins M., Hruban R.H. New markers of pancreatic cancer identified through differential gene expression analyses: claudin 18 and annexin A8. Am. J. Surg. Pathol. 2008, 32:188-196.
117. Kwan V., Church N., Biankin S., Norton I.D., Jones D.B., Falk G.L. Serous cystadenoma causing biliary obstruction with synchronous pancreatic intraepithelial neoplasia. Gastrointest. Endosc. 2006, 64:291-294.
118. Barbu S.T., Domsa I., Cazacu M. Progression of Pancreatic Intraepithelial Neoplasia to Invasive Adenocarcinoma in Chronic Pancreatitis Patients 2008, 461-462.
119. Hisa T., Suda K., Nobukawa B., Ohkubo H., Shiozawa S., Ishigame H., Yamao K., Yatabe Y. Distribution of intraductal lesions in small invasive ductal carcinoma of the pancreas. Pancreatology 2007, 7:341-346.
120. Esposito I., Seiler C., Bergmann F., Kleeff J., Friess H., Schirmacher P. Hypothetical progression model of pancreatic cancer with origin in the centroacinar-acinar compartment. Pancreas 2007, 35:212-217.
121. Shi G., Zhu L., Sun Y., Bettencourt R., Damsz B., Hruban R.H., Konieczny S.F. Loss of the acinar-restricted transcription factor Mist1 accelerates Kras-induced pancreatic intraepithelial neoplasia. Gastroenterology 2009, 136:1368-1378.
122. Lin Y., Goedegebuure P.S., Tan M.C., Gross J., Malone J.P., Feng S., Larson J., Phommaly C., Trinkaus K., Townsend R.R., Linehan D.C. Proteins associated with disease and clinical course in pancreas cancer: a proteomic analysis of plasma in surgical patients. J. Proteome. Res. 2006, 5:2169-2176.
123. Rong Y., Jin D., Hou C., Hu J., Wu W., Ni X., Wang D., Lou W. Proteomics analysis of serum protein profiling in pancreatic cancer patients by DIGE: up-regulation of mannose-binding lectin 2 and myosin light chain kinase 2. BMC Gastroenterol. 2010, 10:68.
124. Orchekowski R., Hamelinck D., Li L., Gliwa E., vanBrocklin M., Marrero J.A., Vande Woude G.F., Feng Z., Brand R., Haab B.B. Antibody microarray profiling reveals individual and combined serum proteins associated with pancreatic cancer. Cancer Res. 2005, 65:11193-11202.
125. Takano S., Sogawa K., Yoshitomi H., Shida T., Mogushi K., Kimura F., Shimizu H., Yoshidome H., Ohtsuka M., Kato A., Ishihara T., Tanaka H., Yokosuka O., Nomura F., Miyazaki M. Increased circulating cell signalling phosphoproteins in sera are useful for the detection of pancreatic cancer. Br. J. Cancer 2010, 103:223-231.
126. Gronborg M., Kristiansen T.Z., Iwahori A., Chang R., Reddy R., Sato N., Molina H., Jensen O.N., Hruban R.H., Goggins M.G., Maitra A., Pandey A. Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol. Cell. Proteomics 2006, 5:157-171.
127. Bhattacharyya S., Siegel E.R., Petersen G.M., Chari S.T., Suva L.J., Haun R.S. Diagnosis of pancreatic cancer using serum proteomic profiling. Neoplasia 2004, 6:674-686.
128. Bloomston M., Zhou J.X., Rosemurgy A.S., Frankel W., Muro-Cacho C.A., Yeatman T.J. Fibrinogen gamma overexpression in pancreatic cancer identified by large-scale proteomic analysis of serum samples. Cancer Res. 2006, 66:2592-2599.
129. Honda K., Hayashida Y., Umaki T., Okusaka T., Kosuge T., Kikuchi S., Endo M., Tsuchida A., Aoki T., Itoi T., Moriyasu F., Hirohashi S., Yamada T. Possible detection of pancreatic cancer by plasma protein profiling. Cancer Res. 2005, 65:10613-10622.
130. Navaglia F., Fogar P., Basso D., Greco E., Padoan A., Tonidandel L., Fadi E., Zambon C.F., Bozzato D., Moz S., Seraglia R., Pedrazzoli S., Plebani M. Pancreatic cancer biomarkers discovery by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry. Clin. Chem. Lab. Med. 2009, 47:713-723.
131. Gold D.V., Modrak D.E., Ying Z., Cardillo T.M., Sharkey R.M., Goldenberg D.M. New MUC1 serum immunoassay differentiates pancreatic cancer from pancreatitis. J. Clin. Oncol. 2006, 24:252-258.
132. Jiang J.T., Wu C.P., Deng H.F., Lu M.Y., Wu J., Zhang H.Y., Sun W.H., Ji M. Serum level of TSGF, CA242 and CA19-9 in pancreatic cancer. World J. Gastroenterol. 2004, 10:1675-1677.
133. Koopmann J., Rosenzweig C.N., Zhang Z., Canto M.I., Brown D.A., Hunter M., Yeo C., Chan D.W., Breit S.N., Goggins M. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin. Cancer Res. 2006, 12:442-446.
134. Chen R., Pan S., Yi E.C., Donohoe S., Bronner M.P., Potter J.D., Goodlett D.R., Aebersold R., Brentnall T.A. Quantitative proteomic profiling of pancreatic cancer juice. Proteomics 2006, 6:3871-3879.
135. Chen R., Pan S., Cooke K., Moyes K.W., Bronner M.P., Goodlett D.R., Aebersold R., Brentnall T.A. Comparison of pancreas juice proteins from cancer versus pancreatitis using quantitative proteomic analysis. Pancreas 2007, 34:70-79.
136. Carrigan P.E., Hentz J.G., Gordon G., Morgan J.L., Raimondo M., Anbar A.D., Miller L.J. Distinctive heavy metal composition of pancreatic juice in patients with pancreatic carcinoma. Cancer Epidemiol. Biomark. Prev. 2007, 16:2656-2663.
137. Yoshida K., Ueno S., Iwao T., Yamasaki S., Tsuchida A., Ohmine K., Ohki R., Choi Y.L., Koinuma K., Wada T., Ota J., Yamashita Y., Chayama K., Sato K., Mano H. Screening of genes specifically activated in the pancreatic juice ductal cells from the patients with pancreatic ductal carcinoma. Cancer Sci. 2003, 94:263-270.
138. Rosty C., Christa L., Kuzdzal S., Baldwin W.M., Zahurak M.L., Carnot F., Chan D.W., Canto M., Lillemoe K.D., Cameron J.L., Yeo C.J., Hruban R.H., Goggins M. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Res. 2002, 62:1868-1875.
139. Chen R., Pan S., Duan X., Nelson B.H., Sahota R.A., de R.S., Kozarek R.A., McIntosh M., Brentnall T.A. Elevated level of anterior gradient-2 in pancreatic juice from patients with pre-malignant pancreatic neoplasia. Mol. Cancer 2010, 9:149.
140. Rogers C.D., Fukushima N., Sato N., Shi C., Prasad N., Hustinx S.R., Matsubayashi H., Canto M., Eshleman J.R., Hruban R.H., Goggins M. Differentiating pancreatic lesions by microarray and QPCR analysis of pancreatic juice RNAs. Cancer Biol. Ther. 2006, 5:1383-1389.
141. Nakashima A., Murakami Y., Uemura K., Hayashidani Y., Sudo T., Hashimoto Y., Ohge H., Oda M., Sueda T., Hiyama E. Usefulness of human telomerase reverse transcriptase in pancreatic juice as a biomarker of pancreatic malignancy. Pancreas 2009, 38:527-533.
142. Tian R., Wei L.M., Qin R.Y., Li Y., Du Z.Y., Xia W., Shi C.J., Jin H. Proteome analysis of human pancreatic ductal adenocarcinoma tissue using two-dimensional gel electrophoresis and tandem mass spectrometry for identification of disease-related proteins. Dig. Dis. Sci. 2008, 53:65-72.
143. Zhou L., Lu Z., Yang A., Deng R., Mai C., Sang X., Faber K.N., Lu X. Comparative proteomic analysis of human pancreatic juice: methodological study. Proteomics 2007, 7:1345-1355.
144. Yan L., Tonack S., Smith R., Dodd S., Jenkins R.E., Kitteringham N., Greenhalf W., Ghaneh P., Neoptolemos J.P., Costello E. Confounding effect of obstructive jaundice in the interpretation of proteomic plasma profiling data for pancreatic cancer. J. Proteome Res. 2009, 8:142-148.
145. Mark E.Weeks, Hariharan Deepak, Petronijevic Ljiljana, Radon Tomasz P., Whiteman Hannah J., Kocher Hemant M., Timms John F., Lemoine Nicholas R., Cmogorac-Jurcevic Tatjana Analysis of the urine proteome in patients with pancreatic ductal adenocarcinoma. Proteomics Clin. Applic. 2008, 2:1047-1057.
146. Farina A., Dumonceau J.M., Frossard J.L., Hadengue A., Hochstrasser D.F., Lescuyer P. Proteomic analysis of human bile from malignant biliary stenosis induced by pancreatic cancer. J. Proteome. Res. 2009, 8:159-169.
147. Moniaux N., Chakraborty S., Yalniz M., Gonzalez J., Shostrom V.K., Standop J., Lele S.M., Ouellette M., Pour P.M., Sasson A.R., Brand R.E., Hollingsworth M.A., Jain M., Batra S.K. Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia. Br. J. Cancer 2008, 98:1540-1547.
148. Ustundag Y., Bayraktar Y. Cholangiocarcinoma: a compact review of the literature. World J. Gastroenterol. 2008, 14:6458-6466.
149. Gowda G.A. Human bile as a rich source of biomarkers for hepatopancreatobiliary cancers. Biomark. Med. 2010, 4:299-314.
150. Zhu Z., Gao W., Qian Z., Miao Y. Genetic variation of miRNA sequence in pancreatic cancer. Acta Biochim. Biophys. Sin. (Shanghai) 2009, 41:407-413.
151. Calin G.A., Ferracin M., Cimmino A., Di L.G., Shimizu M., Wojcik S.E., Iorio M.V., Visone R., Sever N.I., Fabbri M., Iuliano R., Palumbo T., Pichiorri F., Roldo C., Garzon R., Sevignani C., Rassenti L., Alder H., Volinia S., Liu C.G., Kipps T.J., Negrini M., Croce C.M. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N. Engl. J. Med. 2005, 353:1793-1801.
152. Habbe N., Koorstra J.-B.M., Mendell J.R., Offerhaus G.J., Ryu J.K., Feldmann G., Mllendore M.E., Goggins M.G., Hong S.-M., Maitra A. MicroRNA Mir-155 Is a Biomarker of Early Pancreatic Neoplasia 2008, 473.
153. Tahira A.C., Kubrusly M.S., Faria M.F., Cunha J.E.M., Jukemura J., Bacchella T., Verjovski-Almeida S., Reis E.M., Machado M.C.C. Identification of Protein-coding and Noncoding Gene Expression Signatures Correlated with Malignant Transformation and Metastases in Pancreatic Cancer 2008, 497.
154. Volinia S., Calin G.A., Liu C.G., Ambs S., Cimmino A., Petrocca F., Visone R., Iorio M., Roldo C., Ferracin M., Prueitt R.L., Yanaihara N., Lanza G., Scarpa A., Vecchione A., Negrini M., Harris C.C., Croce C.M. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:2257-2261.
155. Lee E.J., Gusev Y., Jiang J., Nuovo G.J., Lerner M.R., Frankel W.L., Morgan D.L., Postier R.G., Brackett D.J., Schmittgen T.D. Expression profiling identifies microRNA signature in pancreatic cancer. Int. J. Cancer 2007, 120:1046-1054.
156. Roldo C., Missiaglia E., Hagan J.P., Falconi M., Capelli P., Bersani S., Calin G.A., Volinia S., Liu C.G., Scarpa A., Croce C.M. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J. Clin. Oncol. 2006, 24:4677-4684.
157. Moriyama T., Ohuchida K., Mizumoto K., Yu J., Sato N., Nabae T., Takahata S., Toma H., Nagai E., Tanaka M. MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol. Cancer Ther. 2009.
158. Yan L.X., Huang X.F., Shao Q., Huang M.Y., Deng L., Wu Q.L., Zeng Y.X., Shao J.Y. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 2008, 14:2348-2360.
159. Szafranska A.E., Davison T.S., John J., Cannon T., Sipos B., Maghnouj A., Labourier E., Hahn S.A. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 2007, 26:4442-4452.
160. Szafranska A.E., Doleshal M., Edmunds H.S., Gordon S., Luttges J., Munding J.B., Barth R.J., Gutmann E.J., Suriawinata A.A., Marc P.J., Tannapfel A., Korc M., Hahn S.A., Labourier E., Tsongalis G.J. Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clin. Chem. 2008, 54:1716-1724.
161. Bloomston M., Frankel W.L., Petrocca F., Volinia S., Alder H., Hagan J.P., Liu C.G., Bhatt D., Taccioli C., Croce C.M. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 2007, 297:1901-1908.
162. Dillhoff M., Liu J., Frankel W., Croce C., Bloomston M. MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J. Gastrointest. Surg. 2008, 12:2171-2176.
163. Hartwell L., Mankoff D., Paulovich A., Ramsey S., Swisher E. Cancer biomarkers: a systems approach. Nat. Biotechnol. 2006, 24:905-908.
164. Klein A.P., Brune K.A., Petersen G.M., Goggins M., Tersmette A.C., Offerhaus G.J., Griffin C., Cameron J.L., Yeo C.J., Kern S., Hruban R.H. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 2004, 64:2634-2638.
165. Brand R.E., Lerch M.M., Rubinstein W.S., Neoptolemos J.P., Whitcomb D.C., Hruban R.H., Brentnall T.A., Lynch H.T., Canto M.I. Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut 2007, 56:1460-1469.
166. Michaud D.S. Epidemiology of pancreatic cancer. Minerva Chir. 2004, 59:99-111.
167. Giardiello F.M., Offerhaus G.J., Lee D.H., Krush A.J., Tersmette A.C., Booker S.V., Kelley N.C., Hamilton S.R. Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis. Gut 1993, 34:1394-1396.
168. Greenhalf W., Malats N., Nilsson M., Bartsch D., Neoptolemos J. International registries of families at high risk of pancreatic cancer. Pancreatology 2008, 8:558-565.
169. Hahn S.A., Greenhalf B., Ellis I., Sina-Frey M., Rieder H., Korte B., Gerdes B., Kress R., Ziegler A., Raeburn J.A., Campra D., Grutzmann R., Rehder H., Rothmund M., Schmiegel W., Neoptolemos J.P., Bartsch D.K. BRCA2 germline mutations in familial pancreatic carcinoma. J. Natl. Cancer Inst. 2003, 95:214-221.
170. Kluijt I., Cats A., Fockens P., Nio Y., Gouma D.J., Bruno M.J. Atypical familial presentation of FAMMM syndrome with a high incidence of pancreatic cancer: case finding of asymptomatic individuals by EUS surveillance. J. Clin. Gastroenterol. 2009, 43:853-857.
171. Rulyak S.J., Kimmey M.B., Veenstra D.L., Brentnall T.A. Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds. Gastrointest. Endosc. 2003, 57:23-29.
172. Brat D.J., Lillemoe K.D., Yeo C.J., Warfield P.B., Hruban R.H. Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas. Am. J. Surg. Pathol. 1998, 22:163-169.
173. Warshaw A.L., Fernandez-del C.C. Pancreatic carcinoma. N. Engl. J. Med. 1992, 326:455-465.
174. Goggins M., Schutte M., Lu J., Moskaluk C.A., Weinstein C.L., Petersen G.M., Yeo C.J., Jackson C.E., Lynch H.T., Hruban R.H., Kern S.E. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res. 1996, 56:5360-5364.
175. Murphy K.M., Brune K.A., Griffin C., Sollenberger J.E., Petersen G.M., Bansal R., Hruban R.H., Kern S.E. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res. 2002, 62:3789-3793.
176. Couch F.J., Johnson M.R., Rabe K.G., Brune K., de A.M., Goggins M., Rothenmund H., Gallinger S., Klein A., Petersen G.M., Hruban R.H. The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol. Biomark. Prev. 2007, 16:342-346.
177. Zanini N., Fantini L., Casadei R., Pezzilli R., Santini D., Calculli L., Minni F. Serous cystic tumors of the pancreas: when to observe and when to operate: a single-center experience. Dig. Surg. 2008, 25:233-239.
178. Agarwal B., Krishna N.B., Labundy J.L., Safdar R., Akduman E.I. EUS and/or EUS-guided FNA in patients with CT and/or magnetic resonance imaging findings of enlarged pancreatic head or dilated pancreatic duct with or without a dilated common bile duct. Gastrointest. Endosc. 2008, 68:237-242.
179. Ho S., Bonasera R.J., Pollack B.J., Grendell J., Feuerman M., Gress F. A single-center experience of endoscopic ultrasonography for enlarged pancreas on computed tomography. Clin. Gastroenterol. Hepatol. 2006, 4:98-103.
180. Shi C., Hruban R.H., Klein A.P. Familial pancreatic cancer. Arch. Pathol. Lab. Med. 2009, 133:365-374.
181. Efthimiou E., Crnogorac-Jurcevic T., Lemoine N.R., Brentnall T.A. Inherited predisposition to pancreatic cancer. Gut 2001, 48:143-147.
182. Topazian M., Enders F., Kimmey M., Brand R., Chak A., Clain J., Cunningham J., Eloubeidi M., Gerdes H., Gress F., Jagannath S., Kantsevoy S., LeBlanc J.K., Levy M., Lightdale C., Romagnuolo J., Saltzman J.R., Savides T., Wiersema M., Woodward T., Petersen G., Canto M. Interobserver agreement for EUS findings in familial pancreatic-cancer kindreds. Gastrointest. Endosc. 2007, 66:62-67.
183. Martin S.P., Ulrich C.D. Pancreatic cancer surveillance in a high-risk cohort. Is it worth the cost?. Med. Clin. N. Am. 2000, 84. 739-xiii.
184. Kimmey M.B., Bronner M.P., Byrd D.R., Brentnall T.A. Screening and surveillance for hereditary pancreatic cancer. Gastrointest. Endosc. 2002, 56:S82-S86.
185. Jo H.S. Factors Associated with Screening Behavior of Stomach Cancer based on Socio-Ecological Model: Korean National Study 2005.
186. Chelala C., Lemoine N.R., Hahn S.A., Crnogorac-Jurcevic T. A web-based platform for mining pancreatic expression datasets. Pancreatology 2009, 9:340-343.
187. Tamm E.P., Silverman P.M., Charnsangavej C., Evans D.B. Diagnosis, staging, and surveillance of pancreatic cancer. AJR Am. J. Roentgenol. 2003, 180:1311-1323.
188. Sun Z.L., Zhu Y., Wang F.Q., Chen R., Peng T., Fan Z.N., Xu Z.K., Miao Y. Serum proteomic-based analysis of pancreatic carcinoma for the identification of potential cancer biomarkers. Biochim. Biophys. Acta 2007, 1774:764-771.
189. Kim Y.I. Folate and methylenetetrahydrofolate reductase polymorphisms: new nutritional and genetic risk factors for pancreatic cancer?. Clin. Gastroenterol. Hepatol. 2005, 3:738-742.
190. Nakayama S., Semba S., Maeda N., Aqeilan R.I., Huebner K., Yokozaki H. Role of the WWOX gene, encompassing fragile region FRA16D, in suppression of pancreatic carcinoma cells. Cancer Sci. 2008, 99:1370-1376.
191. Ohuchida K., Mizumoto K., Ishikawa N., Fujii K., Konomi H., Nagai E., Yamaguchi K., Tsuneyoshi M., Tanaka M. The role of S100A6 in pancreatic cancer development and its clinical implication as a diagnostic marker and therapeutic target. Clin. Cancer Res. 2005, 11:7785-7793.
192. Hruban R.H., Takaori K., Klimstra D.S., Adsay N.V., bores-Saavedra J., Biankin A.V., Biankin S.A., Compton C., Fukushima N., Furukawa T., Goggins M., Kato Y., Kloppel G., Longnecker D.S., Luttges J., Maitra A., Offerhaus G.J., Shimizu M., Yonezawa S. An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am. J. Surg. Pathol. 2004, 28:977-987.
193. Sato N., Fukushima N., Hruban R.H., Goggins M. CpG island methylation profile of pancreatic intraepithelial neoplasia. Mod. Pathol. 2008, 21:238-244.
194. Sanada Y., Yoshida K. Immunohistochemical analyses in intraductal gradually transitional components is useful for evaluation of stepwise progression of pancreatic intraepithelial neoplasia. Pancreas 2007, 35:101-103.
195. Cao D., Zhang Q., Wu L.S., Salaria S.N., Winter J.W., Hruban R.H., Goggins M.S., Abbruzzese J.L., Maitra A., Ho L. Prognostic significance of maspin in pancreatic ductal adenocarcinoma: tissue microarray analysis of 223 surgically resected cases. Mod. Pathol. 2007, 20:570-578.
196. Thomas R.M., Kim J., Revelo-Penafiel M.P., Angel R., Dawson D.W., Lowy A.M. The chemokine receptor CXCR4 is expressed in pancreatic intraepithelial neoplasia. Gut 2008, 57:1555-1560.
197. Thomas R.M., Toney K., Fenoglio-Preiser C., Revelo-Penafiel M.P., Hingorani S.R., Tuveson D.A., Waltz S.E., Lowy A.M. The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. Cancer Res. 2007, 67:6075-6082.
198. Peng D.F., Kanai Y., Sawada M., Ushijima S., Hiraoka N., Kosuge T., Hirohashi S. Increased DNA methyltransferase 1 (DNMT1) protein expression in precancerous conditions and ductal carcinomas of the pancreas. Cancer Sci. 2005, 96:403-408.
199. Crnogorac-Jurcevic T., Gangeswaran R., Bhakta V., Capurso G., Lattimore S., Akada M., Sunamura M., Prime W., Campbell F., Brentnall T.A., Costello E., Neoptolemos J., Lemoine N.R. Proteomic analysis of chronic pancreatitis and pancreatic adenocarcinoma. Gastroenterology 2005, 129:1454-1463.